FORUM FOSTERS DIALOGUE BETWEEN BREAST CANCER LIVED EXPERIENCE ADVOCATES, RESEARCHERS AND CLINICIANS Organised by the University of Queensland and Translational Research Institute
In October 2024, the Frazier Institute hosted an event dedicated to breast cancer advocacy and research, supported by TRI (Translational Research Institute), National Breast Cancer Foundation, PA Research Foundation, Health Translation Queensland, QUT and The University of Queensland Faculty of Medicine/Frazer Institute.
The key aim of the event co-organised by Associate Professor Joy Wolfram, Group Leader, Australian Institute for Bioengineering and Nanotechnology & School of Chemical Engineering, The University of Queensland was to foster dialogue between breast cancer lived experience advocates (consumers), researchers, and clinicians.
Co-organiser Associate Professor Fernando Guimaraes, Group Leader, Principal Research Fellow, Frazer Institute, The University of Queensland spoke to Australian Health Journal about the need to host the event and regularly engage with consumers.
Jo Maxwell, Principal Project Officer, Consumer and Community Involvement in Research Strategy and Support at The University of Queensland also spoke about the standards for consumer participation and collaboration adopted from the International Association for Public Participation (IAP2).
“IAP2 guides the researcher to structure consumer involvement all through the different stages of their research”, says Maxwell.
Associate Professor Cleola Anderiesz, Chief Executive Officer National Breast Cancer Foundation presented at the Forum and spoke to Australian Health Journal on the impact of engagement when communities, researchers and clinicians come together to hear about the latest research and discuss a future of better breast cancer care and outcomes.
The day long event was enlightening and impactful. The forum in Brisbane included a workshop focused on creating international connections between breast cancer consumers in Australia and the United States, with insights from leading breast cancer oncologists, clinicians, consumers, researchers, and community.
-
Improved access to technology needed for people with Type 2 Diabetes needing insulin
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.
-
Evolution of the pharmacy tribe
The past 18 months has shown the strength of Australian pharmacies in ensuring accessibility, credibility and maintaining rapport with the community to administer COVID-19 vaccinations, handle electronic prescriptions and looking to play an integrated role in aged care.
-
Lens on patient care & allied health workforce across settings
The CEO of Allied Health Professions Australia (AHPA), Bronwyn Morris-Donovan spoke with Australian Health Journal about the following:
The structure and priorities for AHPA
The setting and disciplines in Allied Health
Allied Health representation in the Strengthening Medicare Task Force
Importance of a data strategy and interoperability in delivery of allied health services
Key allied health priorities hopefully addressed in Federal Budget.In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
